European journal of obstetrics, gynecology, and reproductive biology · 2025
Platelet-rich plasma therapy enhances endometrial receptivity in thin endometrium patients undergoing frozen embryo transfer cycles: results from a prospective cohort observational study.
СтатьяНаблюдательное исследованиеНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Nayar Kanad Dev, Arora Shweta, Sanan Sabina, Sachdeva Manika, Sethi Ankita, Kant Gaurav, Nayar Kapil
Аннотация
OBJECTIVE: To evaluate the impact of intrauterine instillation of autologous platelet-rich plasma (PRP) on women with thin endometrium undergoing frozen embryo transfer.
METHODS: A prospective cohort observational study was carried out at Akanksha IVF Centre, New Delhi, from 1st August 2023 to 31st July 2024. The study included 100 patients under 40 years with thin endometrium (<7 mm on transvaginal sonography). Participants received hormone replacement therapy (sequential incremental dosage of estradiol valerate) from day 2 of the menstrual cycle. Among them, 70 patients received intrauterine PRP instillation on days 7, 9, and 11 of the cycle, while the remaining 30 patients did not undergo this treatment. Endometrial thickness was monitored, and progesterone was initiated on day 14 or once endometrial thickness surpassed 7 mm, followed by blastocyst transfer on day 6 of progesterone. Pregnancy outcomes were assessed using urine pregnancy tests or serum beta human chorionic gonadotropin levels followed by ultrasound to confirm fetal viability. The main outcomes assessed were improvement in endometrial thickness and clinical pregnancy rate.
RESULTS: The administration of PRP through intrauterine instillation significantly increased mean endometrial thickness in the PRP group compared to the non-PRP group (p = 0.032). The clinical pregnancy rate was 35.71 % in the PRP group versus 10 % in the non-PRP group (p = 0.0251). No adverse reactions were observed.
CONCLUSIONS: PRP therapy significantly enhances endometrial receptivity and improves pregnancy outcomes in patients with refractory thin endometrium. It offers a promising adjunctive treatment for patients facing repeated cycle cancellations in frozen embryo transfer.
METHODS: A prospective cohort observational study was carried out at Akanksha IVF Centre, New Delhi, from 1st August 2023 to 31st July 2024. The study included 100 patients under 40 years with thin endometrium (<7 mm on transvaginal sonography). Participants received hormone replacement therapy (sequential incremental dosage of estradiol valerate) from day 2 of the menstrual cycle. Among them, 70 patients received intrauterine PRP instillation on days 7, 9, and 11 of the cycle, while the remaining 30 patients did not undergo this treatment. Endometrial thickness was monitored, and progesterone was initiated on day 14 or once endometrial thickness surpassed 7 mm, followed by blastocyst transfer on day 6 of progesterone. Pregnancy outcomes were assessed using urine pregnancy tests or serum beta human chorionic gonadotropin levels followed by ultrasound to confirm fetal viability. The main outcomes assessed were improvement in endometrial thickness and clinical pregnancy rate.
RESULTS: The administration of PRP through intrauterine instillation significantly increased mean endometrial thickness in the PRP group compared to the non-PRP group (p = 0.032). The clinical pregnancy rate was 35.71 % in the PRP group versus 10 % in the non-PRP group (p = 0.0251). No adverse reactions were observed.
CONCLUSIONS: PRP therapy significantly enhances endometrial receptivity and improves pregnancy outcomes in patients with refractory thin endometrium. It offers a promising adjunctive treatment for patients facing repeated cycle cancellations in frozen embryo transfer.